Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balsalazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 0.68 |
| ▸ | NME4 | O00746 | 3/20 | 0.68 |
| ▸ | GCDH | Q92947 | 3/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.68 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.68 |
| ▸ | HTR3A | P46098 | 1/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balsalazide SCHEMBL1461533 | 0.88 | ADORA3 (0.52) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL29377041 | 0.83 | SIRT5 (1.00) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL3267109 | 0.83 | SIRT5 (1.00) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL138311 | 0.83 | SIRT5 (1.00) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL118300 | 0.83 | SIRT5 (1.00) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL28818120 | 0.82 | SIRT5 (0.97) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL7908058 | 0.82 | SIRT5 (0.97) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL5598491 | 0.82 | SIRT5 (0.97) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL134019 | 0.82 | SIRT5 (0.97) | SIRT5NME4GCDHADORA3TDP1 | |
| Balsalazide SCHEMBL133200 | 0.81 | SIRT5 (0.95) | SIRT5NME4GCDHADORA3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200155491-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-05-21 | — | — | US | disclosed |
| US-10463640-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-11-05 | — | — | US | disclosed |
| US-10441558-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-10-15 | — | — | US | disclosed |
| US-10322101-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-06-18 | — | — | US | disclosed |
| EP-3459535-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2019-03-27 | — | — | EP | disclosed |
| US-20180360785-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-12-20 | — | — | US | disclosed |
| US-20180338969-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-11-29 | — | — | US | disclosed |
| EP-2609916-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-20180250289-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-09-06 | — | — | US | disclosed |
| CN-104257657-B | Treatment method for treating CMT and relevant disease | 法奈科斯公司 | 2017-07-04 | — | — | CN | disclosed |
| US-20150157626-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | NEOVACS S.A. (FR) | 2015-06-11 | — | — | US | disclosed |
| US-8992891-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2609916-A1 | New therapeutic approaches for treating CMT and related disorders | Pharnext (FR) | 2013-07-03 | — | — | EP | disclosed |
| EP-2211846-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |